SA08290041B1 - أدوية من أجل معالجة بطانة الرحم - Google Patents
أدوية من أجل معالجة بطانة الرحم Download PDFInfo
- Publication number
- SA08290041B1 SA08290041B1 SA08290041A SA08290041A SA08290041B1 SA 08290041 B1 SA08290041 B1 SA 08290041B1 SA 08290041 A SA08290041 A SA 08290041A SA 08290041 A SA08290041 A SA 08290041A SA 08290041 B1 SA08290041 B1 SA 08290041B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- dopamine
- endometriosis
- cofactor
- treatment
- day
- Prior art date
Links
- 201000009273 Endometriosis Diseases 0.000 title claims abstract description 58
- 238000011282 treatment Methods 0.000 title claims abstract description 48
- 239000003814 drug Substances 0.000 title claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 123
- 229960003638 dopamine Drugs 0.000 claims description 62
- 229960004596 cabergoline Drugs 0.000 claims description 36
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims description 34
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 21
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 21
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 21
- 102000015554 Dopamine receptor Human genes 0.000 claims description 9
- 108050004812 Dopamine receptor Proteins 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 9
- GDFGTRDCCWFXTG-SCTDSRPQSA-N (3r,4ar,10as)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2h-benzo[g]quinoline Chemical compound C1=CC=C2C[C@@H]3N(CCC)C[C@H](NS(=O)(=O)N(CC)CC)C[C@H]3CC2=C1O GDFGTRDCCWFXTG-SCTDSRPQSA-N 0.000 claims description 7
- 229960000924 quinagolide Drugs 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 229960002802 bromocriptine Drugs 0.000 claims description 5
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 5
- 230000003278 mimic effect Effects 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 3
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 claims description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003805 amantadine Drugs 0.000 claims description 2
- 229960003587 lisuride Drugs 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 229960004851 pergolide Drugs 0.000 claims description 2
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims description 2
- 229960003089 pramipexole Drugs 0.000 claims description 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 2
- 229960001879 ropinirole Drugs 0.000 claims description 2
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 230000003902 lesion Effects 0.000 description 31
- 210000004204 blood vessel Anatomy 0.000 description 25
- 239000007943 implant Substances 0.000 description 23
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 22
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 21
- 230000033115 angiogenesis Effects 0.000 description 20
- 230000002357 endometrial effect Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 210000004907 gland Anatomy 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 8
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 210000004696 endometrium Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 230000003412 degenerative effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 102000001753 Notch4 Receptor Human genes 0.000 description 4
- 108010029741 Notch4 Receptor Proteins 0.000 description 4
- 208000000450 Pelvic Pain Diseases 0.000 description 4
- 238000002357 laparoscopic surgery Methods 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 210000004303 peritoneum Anatomy 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 208000004483 Dyspareunia Diseases 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003527 anti-angiogenesis Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 3
- 229960000766 danazol Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000000399 optical microscopy Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 101100156752 Caenorhabditis elegans cwn-1 gene Proteins 0.000 description 2
- 101100264065 Danio rerio wnt5b gene Proteins 0.000 description 2
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 2
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 102000052547 Wnt-1 Human genes 0.000 description 2
- 108700020987 Wnt-1 Proteins 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 2
- 229960002140 medetomidine Drugs 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 102000009088 Angiopoietin-1 Human genes 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100323232 Mus musculus Ang3 gene Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102220470006 Parvalbumin-like EF-hand-containing protein_Y40A_mutation Human genes 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 206010065951 Retrograde menstruation Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- HSWPZIDYAHLZDD-UHFFFAOYSA-N atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 description 1
- 229960003002 atipamezole Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004190 broad ligament Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003717 douglas' pouch Anatomy 0.000 description 1
- -1 elixirs Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- WPPDXAHGCGPUPK-UHFFFAOYSA-N red 2 Chemical compound C1=CC=CC=C1C(C1=CC=CC=C11)=C(C=2C=3C4=CC=C5C6=CC=C7C8=C(C=9C=CC=CC=9)C9=CC=CC=C9C(C=9C=CC=CC=9)=C8C8=CC=C(C6=C87)C(C=35)=CC=2)C4=C1C1=CC=CC=C1 WPPDXAHGCGPUPK-UHFFFAOYSA-N 0.000 description 1
- 230000006884 regulation of angiogenesis Effects 0.000 description 1
- 230000022910 regulation of vasculogenesis Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229960004558 terguride Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07250429A EP1952813A1 (en) | 2007-02-01 | 2007-02-01 | Medicament for the treatment of endometriosis |
| GB0712626A GB2450533A (en) | 2007-06-29 | 2007-06-29 | Treatment and prevention of endometriosis using dopamine agonists. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA08290041B1 true SA08290041B1 (ar) | 2012-06-05 |
Family
ID=39674574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA08290041A SA08290041B1 (ar) | 2007-02-01 | 2008-01-30 | أدوية من أجل معالجة بطانة الرحم |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8927568B2 (enExample) |
| EP (1) | EP2109449B1 (enExample) |
| JP (1) | JP5211073B2 (enExample) |
| AR (1) | AR065139A1 (enExample) |
| AT (1) | ATE516805T1 (enExample) |
| AU (1) | AU2008211633B2 (enExample) |
| BR (1) | BRPI0806944A2 (enExample) |
| CA (1) | CA2676910C (enExample) |
| DK (1) | DK2109449T3 (enExample) |
| IL (1) | IL200032A (enExample) |
| JO (1) | JO2730B1 (enExample) |
| MX (1) | MX2009008191A (enExample) |
| NZ (1) | NZ578569A (enExample) |
| PL (1) | PL2109449T3 (enExample) |
| PT (1) | PT2109449E (enExample) |
| RU (1) | RU2423146C2 (enExample) |
| SA (1) | SA08290041B1 (enExample) |
| SI (1) | SI2109449T1 (enExample) |
| TW (1) | TWI411436B (enExample) |
| WO (1) | WO2008093247A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010150098A2 (en) * | 2009-06-26 | 2010-12-29 | Ferring International Center Sa | Treatment of endometriosis |
| EP3017809A1 (en) | 2014-11-07 | 2016-05-11 | Ferring B.V. | Drug-device unit containing quinagolide |
| WO2017210117A1 (en) * | 2016-06-02 | 2017-12-07 | Board Of Trustees, Southern Illinois University | Treatment of endometriosis and niclosamide derivatives |
| JP6562332B2 (ja) * | 2017-05-30 | 2019-08-21 | 有限会社イムノ | 活性化ｔ細胞からのｉｌ−８産生を抑制するための組成物 |
| RU2732251C1 (ru) * | 2019-11-29 | 2020-09-14 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" | Способ лечения наружного генитального эндометриоза |
| US20240361338A1 (en) | 2021-08-31 | 2024-10-31 | Ferring B.V. | Diagnosis and treatment of ectopic endometriosis |
| WO2024153752A1 (en) | 2023-01-20 | 2024-07-25 | Ferring B.V. | Stereoselective synthesis of intermediates and synthesis of quinagolids |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0208417A3 (en) * | 1985-06-12 | 1989-09-06 | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu | Use of 1-(8-alpha-ergolinyl)-3,3-diethyl urea derivatives in the treatment of endometritis |
| WO1993003752A1 (en) * | 1991-08-19 | 1993-03-04 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Decapeptide having dopamine stimulating activity |
| US6572879B1 (en) | 1995-06-07 | 2003-06-03 | Alza Corporation | Formulations for transdermal delivery of pergolide |
| US6127401A (en) * | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
| RU2273481C2 (ru) * | 2004-05-27 | 2006-04-10 | Варвара Анатольевна Волкова | Способ повышения эффективности лечения бесплодия, вызванного малыми формами внешнего генитального эндометриоза |
| WO2006117608A1 (en) * | 2005-04-29 | 2006-11-09 | Ferring International Center S.A. | Treatment or prevention of ovarian hyperstimulation syndrome (ohss) using a dopamine agonist |
| WO2010150098A2 (en) * | 2009-06-26 | 2010-12-29 | Ferring International Center Sa | Treatment of endometriosis |
-
2008
- 2008-01-30 SA SA08290041A patent/SA08290041B1/ar unknown
- 2008-02-01 DK DK08751001.2T patent/DK2109449T3/da active
- 2008-02-01 MX MX2009008191A patent/MX2009008191A/es active IP Right Grant
- 2008-02-01 PT PT08751001T patent/PT2109449E/pt unknown
- 2008-02-01 NZ NZ578569A patent/NZ578569A/en not_active IP Right Cessation
- 2008-02-01 PL PL08751001T patent/PL2109449T3/pl unknown
- 2008-02-01 RU RU2009129252/15A patent/RU2423146C2/ru active
- 2008-02-01 WO PCT/IB2008/001273 patent/WO2008093247A2/en not_active Ceased
- 2008-02-01 AU AU2008211633A patent/AU2008211633B2/en not_active Ceased
- 2008-02-01 CA CA2676910A patent/CA2676910C/en active Active
- 2008-02-01 AR ARP080100431A patent/AR065139A1/es not_active Application Discontinuation
- 2008-02-01 SI SI200830385T patent/SI2109449T1/sl unknown
- 2008-02-01 EP EP08751001A patent/EP2109449B1/en active Active
- 2008-02-01 TW TW097103971A patent/TWI411436B/zh not_active IP Right Cessation
- 2008-02-01 AT AT08751001T patent/ATE516805T1/de active
- 2008-02-01 BR BRPI0806944-1A2A patent/BRPI0806944A2/pt not_active Application Discontinuation
- 2008-02-01 US US12/525,342 patent/US8927568B2/en active Active
- 2008-02-01 JP JP2009547780A patent/JP5211073B2/ja active Active
- 2008-02-02 JO JO200833A patent/JO2730B1/en active
-
2009
- 2009-07-23 IL IL200032A patent/IL200032A/en active IP Right Grant
-
2014
- 2014-11-17 US US14/543,478 patent/US9023862B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1134911A1 (en) | 2010-05-20 |
| IL200032A0 (en) | 2010-04-15 |
| SI2109449T1 (sl) | 2011-11-30 |
| WO2008093247A2 (en) | 2008-08-07 |
| RU2009129252A (ru) | 2011-03-10 |
| US20150073010A1 (en) | 2015-03-12 |
| RU2423146C2 (ru) | 2011-07-10 |
| AU2008211633B2 (en) | 2011-04-21 |
| US9023862B2 (en) | 2015-05-05 |
| IL200032A (en) | 2015-06-30 |
| EP2109449B1 (en) | 2011-07-20 |
| JP5211073B2 (ja) | 2013-06-12 |
| PL2109449T3 (pl) | 2011-12-30 |
| AR065139A1 (es) | 2009-05-20 |
| AU2008211633A1 (en) | 2008-08-07 |
| JO2730B1 (en) | 2013-09-15 |
| PT2109449E (pt) | 2011-11-02 |
| US8927568B2 (en) | 2015-01-06 |
| BRPI0806944A2 (pt) | 2014-05-06 |
| CA2676910A1 (en) | 2008-08-07 |
| WO2008093247A3 (en) | 2008-12-04 |
| TW200845989A (en) | 2008-12-01 |
| ATE516805T1 (de) | 2011-08-15 |
| US20100113499A1 (en) | 2010-05-06 |
| DK2109449T3 (da) | 2011-09-12 |
| EP2109449A2 (en) | 2009-10-21 |
| MX2009008191A (es) | 2009-08-12 |
| NZ578569A (en) | 2011-08-26 |
| CA2676910C (en) | 2012-01-03 |
| JP2010517992A (ja) | 2010-05-27 |
| TWI411436B (zh) | 2013-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Porpora et al. | Pain and ovarian endometrioma recurrence after laparoscopic treatment of endometriosis: a long-term prospective study | |
| Seracchioli et al. | Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial | |
| Efstathiou et al. | Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model | |
| Köhler et al. | A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis | |
| US20220152053A1 (en) | Methods and compositions for treating various disorders | |
| Schlaff et al. | Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain | |
| SA08290041B1 (ar) | أدوية من أجل معالجة بطانة الرحم | |
| CN112020360B (zh) | 化合物以及它们在缓解绝经相关症状中的用途 | |
| Ghezzi et al. | Minimizing ancillary ports size in gynecologic laparoscopy: a randomized trial | |
| WO2017181187A1 (en) | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate | |
| Adachi et al. | A Vonoprazan, clarithromycin, and metronidazole regimen as Helicobacter pylori eradication therapy for patients with penicillin allergy in light of clarithromycin resistance | |
| Lal et al. | Efficacy of mifepristone in reducing intermenstrual vaginal bleeding in users of the levonorgestrel intrauterine system | |
| Robertson et al. | Effects of fulvestrant 250 mg in premenopausal women with oestrogen receptor-positive primary breast cancer | |
| US20140194460A1 (en) | Treatment of endometriosis | |
| CN101641098B (zh) | 用于治疗子宫内膜异位的药物 | |
| KR101160225B1 (ko) | 자궁 내막증 치료용 약제 | |
| HK1134911B (en) | Medicament for the treatment of endometriosis | |
| GB2450533A (en) | Treatment and prevention of endometriosis using dopamine agonists. | |
| Shang et al. | Analysis of risk factors associated with recurrence of granulomatous lobular mastitis and establishment of a prediction model | |
| Pisano et al. | Diagnostic performance of digital versus film mammography for breast-cancer screening | |
| Behbehani et al. | Precis | |
| Fischer et al. | Advances in Endometriosis Research: From Bench to Bedside | |
| Desai | Endometriosis-ECAB |